Immunotherapy before surgery for clear cell kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have clear cell kidney cancer confirmed by biopsy, which has not spread to other parts of the body.
- Your tumor is 4–7 cm located near the kidney center, or larger than 7 cm, making partial nephrectomy challenging.
- You are willing to have kidney-sparing surgery and are healthy enough for general anesthesia.
- You are 18–85 years old, with a good performance status (able to do daily activities).
- Your kidneys function well (healthy kidney GFR at least 60), and your blood counts and liver function are within acceptable limits.
- You have not had other cancers recently, do not have active autoimmune disease, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests combining two drugs (cardenilimab and lenvatinib) before surgery for clear cell kidney cancer that can be removed. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests giving two medications (a PD-L1 inhibitor and anlotinib) before surgery for complex kidney cancer, to try to shrink the tumor enough that surgeons can remove just part of the kidney instead of the whole organ. The goal is to preserve kidney function and avoid dialysis.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to remove a kidney tumor. The goal is to see if this approach is safe and helps shrink tumors in patients with advanced but non-spreading kidney cancer.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.